Astrazeneca PLC (AZN): Price and Financial Metrics
Astrazeneca PLC (AZN)
Today's Latest Price: $53.50 USD
Updated May 28 6:30pm
Add AZN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AZN Stock Summary
- With a market capitalization of $136,526,940,000, Astrazeneca Plc has a greater market value than 98.96% of US stocks.
- With a price/earnings ratio of 111.27, Astrazeneca Plc P/E ratio is greater than that of about 94.6% of stocks in our set with positive earnings.
- In terms of volatility of its share price, AZN is more volatile than only 3.9% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Astrazeneca Plc are AMGN, LLY, SAP, BMY, and TMO.
- Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to www.astrazeneca.com.
AZN Stock Price Chart More Charts
AZN Price/Volume Stats
| Current price | $53.50 | 52-week high | $57.44 |
| Prev. close | $52.47 | 52-week low | $36.15 |
| Day low | $53.42 | Volume | 4,474,832 |
| Day high | $54.04 | Avg. volume | 4,382,360 |
| 50-day MA | $48.80 | Dividend yield | 3.54% |
| 200-day MA | $47.35 | Market Cap | 140.40B |
Astrazeneca PLC (AZN) Company Bio
AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $53.50 | $14.52 | -72% |
We started the process of determining a valid price forecast for Astrazeneca Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Astrazeneca Plc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for AZN, they are:
- The company's compound free cash flow growth rate over the past 5.55 years comes in at -0.12%; that's greater than merely 15.14% of US stocks we're applying DCF forecasting to.
- Relative to other stocks in its sector (Healthcare), Astrazeneca Plc has a reliance on debt greater than 63.79% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -73% |
| 1% | -73% |
| 2% | -72% |
| 3% | -72% |
| 4% | -72% |
| 5% | -72% |
Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See PRGO, CPIX, PBYI, NRC, and RMD.
Loading social stream, please wait...